張文娣 張梅 白金月 徐蒙莉 劉慧 陳文芳
[摘要]?目的?探討淫羊藿素(ICT)對(duì)脂多糖(LPS)誘導(dǎo)的原代星形膠質(zhì)細(xì)胞炎癥反應(yīng)的抑制作用及雌激素受體(ER)阻斷劑ICI182,780對(duì)其影響。
方法常規(guī)培養(yǎng)原代星形膠質(zhì)細(xì)胞,將其分為對(duì)照組、LPS組、ICT+LPS組、ICI182,780+ICT+LPS組、ICI182,780組。對(duì)照組給予1 g/L二甲基亞砜處理,其余各組在有或無(wú)ICT預(yù)處理?xiàng)l件下,先加入1 μmol/L的ICI182,780作用1 h,然后加入10 μmol/L的ICT預(yù)保護(hù)1 h,繼以1 mg/L的LPS作用細(xì)胞6 h。應(yīng)用實(shí)時(shí)熒光定量PCR(RT-PCR)檢測(cè)各組環(huán)氧化酶2(COX-2)和誘導(dǎo)型一氧化氮合酶(iNOS)基因的表達(dá)。
結(jié)果與對(duì)照組比較,LPS組COX-2和iNOS基因的表達(dá)明顯上調(diào)(F=18.19、394.80,q=8.89、41.74,P<0.01);ICT預(yù)保護(hù)能明顯降低由LPS誘導(dǎo)的COX-2和iNOS基因表達(dá)的上調(diào)(q=7.44、13.83,P<0.01),此作用可以被ER特異性阻斷劑ICI182,780所阻斷(q=6.80、8.80,P<0.01);ICI182,780組二者表達(dá)與對(duì)照組相比差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。
結(jié)論ICT能夠抑制LPS誘導(dǎo)的原代星形膠質(zhì)細(xì)胞COX-2和iNOS基因的表達(dá),其抗炎機(jī)制與ER途徑的激活有關(guān)。
[關(guān)鍵詞]?淫羊藿素;脂多糖類;星形細(xì)胞;環(huán)氧化酶2;一氧化氮合酶
[中圖分類號(hào)]?R338.2;R592
[文獻(xiàn)標(biāo)志碼]?A
[文章編號(hào)]??2096-5532(2019)01-0032-04
EFFECT OF ICARITIN ON LIPOPOLYSACCHARIDE-INDUCED GENE EXPRESSION OF CYCLOOXYGENASE-2 AND INDU-CIBLE NITRIC OXIDE SYNTHASE IN PRIMARY CULTURED ASTROCYTES
ZHANG Wendi, ZHANG Mei, BAI Jinyue, XU Mengli, LIU Hui, CHEN Wenfang
(Department of Physiology and Pathophysiology, School of Basic Medicine, Qingdao University, Qingdao 266071, Cnina)
[ABSTRACT]ObjectiveTo investigate the inhibitory effect of icaritin (ICT) on lipopolysaccharide (LPS)-induced inflammatory response in primary cultured astrocytes and the influence of the estrogen receptor (ER) antagonist ICI182,780.
Methods
Primary cultured astrocytes were obtained with conventional methods and then divided into control group, LPS group, ICT+LPS group, ICI182,780+ICT+LPS group, and ICI182,780 group. The control group was treated with 1 g/L dimethyl sulfoxide; the other groups were treated with 1 μmol/L ICI182,780 for 1 h, followed by 10 μmol/L ICT for pre-protection for 1 hour and 1 mg/L LPS for 6 h, with or without ICT pretreatment. Quantitative real-time PCR was used to measure the gene expression of cycloo-xygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS).
ResultsCompared with the control group, the LPS group had significantly upregulated mRNA expression of COX-2 and iNOS (F=18.19 and 394.80,q=8.89 and 41.74,P<0.01). ICT pretreatment significantly inhibited the upregulated mRNA expression of COX-2 and iNOS induced by LPS (q=7.44 and 13.83,P<0.01), which was blocked by the specific ER antagonist ICI182,780 (q=6.80 and 8.80,P<0.01). There was no significant difference in the mRNA expression of COX-2 and iNOS between the ICI182,780 group and the control group (P>0.05).
ConclusionICT can inhibit LPS-induced mRNA expression of COX-2 and iNOS in primary cultured astrocytes, and its anti-inflammatory mechanism might be associated with the activation of the ER pathway.
[KEY WORDS]icaritin; lipopolysaccharides; astrocytes; cyclooxygenase 2; nitric oxide synthase
星形膠質(zhì)細(xì)胞是中樞神經(jīng)系統(tǒng)中數(shù)量最多、分布最廣、體積最大的膠質(zhì)細(xì)胞[1],在維持中樞神經(jīng)系統(tǒng)內(nèi)環(huán)境穩(wěn)態(tài)、支持營(yíng)養(yǎng)神經(jīng)元、參與免疫應(yīng)答等方面起著重要作用[2]。星形膠質(zhì)細(xì)胞適度激活后可釋放多種神經(jīng)營(yíng)養(yǎng)因子,發(fā)揮神經(jīng)元保護(hù)作用[3]。但過(guò)度激活的星形膠質(zhì)細(xì)胞會(huì)釋放大量的神經(jīng)炎性因子如白細(xì)胞介素-1β(IL-1β)、白細(xì)胞介素-6(IL-6)、環(huán)氧化酶-2(COX-2)、腫瘤壞死因子-α(TNF-a)和一氧化氮(NO)等[4-5],引起神經(jīng)系統(tǒng)炎性病變、突觸功能障礙及神經(jīng)元死亡,進(jìn)而引發(fā)相關(guān)的神經(jīng)系統(tǒng)疾病如帕金森病、阿爾茨海默病[6]。因此,抑制活化星形膠質(zhì)細(xì)胞炎性因子的過(guò)度釋放,找到對(duì)抗炎癥反應(yīng)的潛在靶標(biāo),對(duì)于神經(jīng)系統(tǒng)退行性疾病的治療具有重要意義。近年來(lái)中藥治療神經(jīng)炎癥反應(yīng)的研究取得了一定的進(jìn)展,淫羊藿素(ICT)作為傳統(tǒng)補(bǔ)益中藥淫羊藿苷的水解衍生物,能夠發(fā)揮雌激素樣的神經(jīng)保護(hù)和抗炎作用[7]。已有研究證實(shí),在體外細(xì)胞水平ICT具有抗炎作用,能夠抑制脂多糖(LPS)誘導(dǎo)的小鼠RAW264.7巨噬細(xì)胞產(chǎn)生TNF-α、IL-1β、NO和前列腺素E2(PGE2);在整體動(dòng)物水平,ICT能夠降低LPS誘導(dǎo)的C57BL/6J小鼠炎癥模型血清中TNF-α和PGE2的水平及嗜中性粒細(xì)胞CD11b的表達(dá)[8-9]。此外,ICT能夠通過(guò)雌激素依賴的信號(hào)途徑對(duì)抗β淀粉樣蛋白誘導(dǎo)的原代大鼠神經(jīng)元毒性反應(yīng)[10]。那么,ICT能否通過(guò)雌激素受體(ER)抑制星形膠質(zhì)細(xì)胞的炎癥反應(yīng),目前尚不清楚。本研究應(yīng)用LPS制備原代星形膠質(zhì)細(xì)胞的炎癥模型,觀察ICT對(duì)LPS誘導(dǎo)的COX-2和誘導(dǎo)型一氧化氮合酶(iNOS)基因表達(dá)的影響以及ER特異性阻斷劑的阻斷效應(yīng),以期為中樞神經(jīng)系統(tǒng)炎癥相關(guān)疾病的治療提供新靶點(diǎn)。
1?材料與方法
1.1?材料及其來(lái)源
ICT購(gòu)于上海同田生物公司;DMEM/F12培養(yǎng)基購(gòu)自美國(guó)Hyclone公司;LPS和ICI182,780由美國(guó)Sigma公司提供;TRIzol購(gòu)自美國(guó)Life Technologies公司;PCR逆轉(zhuǎn)錄試劑盒購(gòu)自Roche公司;SYBR Green購(gòu)自美國(guó)Takara公司;新生SD大鼠購(gòu)自濟(jì)南朋悅實(shí)驗(yàn)動(dòng)物繁育有限公司。
1.2?細(xì)胞培養(yǎng)及分組
顯微鏡下分離新生SD大鼠中腦,將其置于含有高糖培養(yǎng)基的培養(yǎng)皿中,去除腦膜和血管,分別用1 000、200、10 μL槍頭輕輕吹打,使腦組織呈離散狀態(tài),收集細(xì)胞懸液至大離心管中,離心,棄上清,加入含體積分?jǐn)?shù)0.10胎牛血清、100 kU/L青霉素和100 mg/L鏈霉素的DMEM高糖培養(yǎng)液,將細(xì)胞接種到培養(yǎng)瓶中,于37 ℃、含體積分?jǐn)?shù)0.05的CO2培養(yǎng)箱中差速黏附處理30 min,更換新培養(yǎng)瓶繼續(xù)培養(yǎng)7~10 d,待細(xì)胞長(zhǎng)滿瓶底時(shí),置于37 ℃搖床中以210 r/min振蕩16~18 h,更換新鮮培養(yǎng)液,用胰酶消化法收集細(xì)胞進(jìn)行實(shí)驗(yàn)。將原代培養(yǎng)的星形膠質(zhì)細(xì)胞分為對(duì)照組(A組)、LPS組(B組)、ICT+LPS組(C組)、ICI182,780+ICT+LPS組(D組)以及ICI182,780組(E組)。對(duì)照組給予1 g/L的二甲基亞砜處理;LPS組加入1 mg/L的LPS作用6 h;ICT+LPS組在加LPS前先用10 μmol/L的ICT預(yù)保護(hù)1 h;ICI182,780組和ICI182,780+ICT+LPS組均加入1 μmol/L的ICI182,780作用細(xì)胞1 h,然后ICI182,780+ICT+LPS組加入ICT預(yù)保護(hù)1 h,再加入LPS作用6 h。
1.3實(shí)時(shí)熒光定量PCR(RT-PCR)檢測(cè)COX-2和iNOS mRNA水平
采用Trizol法提取總RNA,取2 μg總RNA加入1 μL錨定的寡聚(dT)18引物和DEPC水,使總體積達(dá)到13 μL,55 ℃變性10 min;加入7 μL的反應(yīng)體系(內(nèi)含逆轉(zhuǎn)錄酶RT 0.5 μL、RNase抑制劑0.5 μL、緩沖液4.0 μL、dNTP 2.0 μL),55 ℃作用30 min,繼以85 ℃作用5 min逆轉(zhuǎn)錄合成cDNA。采用SYBR Green染料法定量檢測(cè)COX-2、iNOS和GAPDH的基因表達(dá)[11]。大鼠原代星形膠質(zhì)細(xì)胞擴(kuò)增引物及其序列見表1。采用2-△△CT法計(jì)算基因相對(duì)表達(dá)量。
1.4?統(tǒng)計(jì)學(xué)處理
實(shí)驗(yàn)所得計(jì)量資料結(jié)果以[AKx-D]±s形式表示,應(yīng)用GraphPad Prism 5.0統(tǒng)計(jì)軟件進(jìn)行單因素方差分析(One-Way ANOVA),并繼以Tukey法進(jìn)行兩兩比較。以P<0.05為差異有顯著性。
2?結(jié)??果
與對(duì)照組相比,LPS組COX-2和iNOS基因表達(dá)明顯上調(diào)(F=18.19、394.80,q=8.89、41.74,P<0.01);ICT+LPS組COX-2和iNOS基因表達(dá)水平較LPS組均明顯降低,差異有統(tǒng)計(jì)學(xué)意義(q=7.44、13.83,P<0.01);而ICT的抗炎作用可以被ICI182,780所阻斷,ICI182,780+ICT+LPS組COX-2和iNOS基因表達(dá)較ICT+LPS組明顯升高,差異有統(tǒng)計(jì)學(xué)意義(q=6.80、8.80,P<0.01);ICI182,780組二者表達(dá)與對(duì)照組相比差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。見表2。
3?討??論
研究表明,星形膠質(zhì)細(xì)胞通過(guò)合成和分泌多種神經(jīng)營(yíng)養(yǎng)因子、趨化因子以及細(xì)胞因子,參與神經(jīng)系統(tǒng)的免疫反應(yīng)[12]。在腦缺血、損傷或感染等病理情況下,星形膠質(zhì)細(xì)胞被激活,激活后的星形膠質(zhì)細(xì)胞釋放大量的炎性因子(如TNF-α、IL-6、NO、PGE2等),這些炎性因子作用于鄰近的細(xì)胞引起炎癥反應(yīng),造成神經(jīng)元損傷[13-14]。因此,有效抑制星形膠質(zhì)細(xì)胞的炎癥反應(yīng),減少炎性因子的釋放,將對(duì)中樞神經(jīng)系統(tǒng)的神經(jīng)退行性疾病以及炎癥相關(guān)病變起到有效的治療作用[15]。
淫羊藿是傳統(tǒng)的中藥材,具有補(bǔ)腎壯陽(yáng)、強(qiáng)筋骨等作用[16]。ICT是淫羊藿的主要活性成分淫羊藿苷的衍生物,能發(fā)揮類雌激素樣的神經(jīng)保護(hù)和抗炎作用[17]。本課題組在前期工作中已經(jīng)證實(shí),ICT能夠?qū)筂PP+誘導(dǎo)的MES23.5細(xì)胞損傷[11]。LPS作為革蘭陰性菌細(xì)胞壁的組成成分,具有很強(qiáng)的致炎作用,可以與細(xì)胞膜上的Toll樣受體4(TLR4)結(jié)合,通過(guò)NF-κB與MAPKs信號(hào)通路介導(dǎo)原代星形膠質(zhì)細(xì)胞的炎癥反應(yīng)[18-19]。本實(shí)驗(yàn)應(yīng)用LPS制備原代星形膠質(zhì)細(xì)胞的炎癥模型,結(jié)果顯示,應(yīng)用1 mg/L的LPS處理原代星形膠質(zhì)細(xì)胞,能夠顯著提高COX-2和iNOS的基因表達(dá)。COX-2在炎癥反應(yīng)中發(fā)揮重要作用,是前列腺素合成的關(guān)鍵限速酶,可以催化細(xì)胞產(chǎn)生前列腺素,參與炎癥反應(yīng)[20]。iNOS能夠催化產(chǎn)生促炎因子NO[4]。近年來(lái),隨著分子生物學(xué)的發(fā)展及雌激素在臨床上的廣泛應(yīng)用[21],對(duì)ER介導(dǎo)的信號(hào)轉(zhuǎn)導(dǎo)途徑及其作用的研究日趨活躍[22]。雌激素可通過(guò)核受體ERα和ERβ介導(dǎo)的基因組途徑,發(fā)揮多種生理作用[23]。有研究顯示,ICT能夠促進(jìn)乳癌MCF-7細(xì)胞增殖,進(jìn)一步的機(jī)制研究揭示ICT對(duì)MCF-7、T47D乳癌細(xì)胞的促增殖作用與ER有關(guān)[24]。在神經(jīng)系統(tǒng),ICT能夠通過(guò)雌激素依賴的信號(hào)途徑對(duì)抗β淀粉樣蛋白誘導(dǎo)的原代大鼠神經(jīng)元的毒性反應(yīng)[10]。但在原代星形膠
質(zhì)細(xì)胞,ICT是否通過(guò)ER發(fā)揮其抗炎作用,目前尚
未見報(bào)道。本實(shí)驗(yàn)研究結(jié)果顯示,用10 μmol/L的ICT預(yù)保護(hù)原代星形膠質(zhì)細(xì)胞,能夠明顯抑制LPS誘導(dǎo)的COX-2和iNOS基因表達(dá)上調(diào),提示ICT對(duì)原代星形膠質(zhì)細(xì)胞具有明顯的抗炎作用;而進(jìn)一步的實(shí)驗(yàn)結(jié)果也顯示,應(yīng)用核受體ER特異性阻斷劑ICI182,780能夠阻斷ICT的抗炎作用,表明ER參與了ICT的抗炎作用。
綜上所述,ICT能夠抑制LPS誘導(dǎo)的原代星形膠質(zhì)細(xì)胞COX-2和iNOS基因的表達(dá),其抗炎機(jī)制與ER信號(hào)途徑的激活有關(guān)。
[參考文獻(xiàn)]
[1]OKUDA H. A review of functional heterogeneity among astrocytes and the CS56-specific antibody-mediated detection of a subpopulation of astrocytes in adult brains[J]. ?Anatomical Science International, 2018,93(2):161-168.
[2]MANDREKAR-COLUCCI S, SAUERBECK A, POPOVICH P G, et al. PPAR agonists as therapeutics for CNS trauma and neurological diseases[J]. ?ASN Neuro, 2013,5(5):e00129.
[3]HE Xiaosong, LIU Yanqun, LIN Xiaohong, et al. Netrin-1 attenuates brain injury after middle cerebral artery occlusion via downregulation of astrocyte activation in mice[J]. ?Journal of Neuroinflammation, 2018,15(1):268.
[4]張學(xué)杰,任曉璠,陳文芳. Rg1對(duì)膠質(zhì)細(xì)胞iNOS基因表達(dá)的抑制作用及RU486對(duì)其影響[J]. ?青島大學(xué)醫(yī)學(xué)院學(xué)報(bào), 2017,53(2):133-135,139.
[5]RYU J K, CHO T, CHOI H B, et al. Pharmacological anta-gonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimers disease[J]. ?Journal of Neuroinflammation, 2015,12(1):144.
[6]THEODORE S, CAO S W, MCLEAN P J, et al. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease[J]. ?Journal of Neuropathology and Expe-rimental Neurology, 2008,67(12):1149-1158.
[7]楊珍,王媛,張艷軍,等. 基于細(xì)胞萃取及分子對(duì)接的淫羊藿中雌激素樣作用成分分析[J]. ?中國(guó)實(shí)驗(yàn)方劑學(xué)雜志, 2016,22(20):62-66.
[8]WU Jinfeng, DU Juan, XU Changqing, et al. In vivo and in vitro anti-inflammatory effects of a novel derivative of icariin[J]. ?Immunopharmacology and Immunotoxicology, 2011,33(1,1):49-54.
[9]賴新強(qiáng),黃秀艷,曾耀英. 脫水淫羊藿素對(duì)小鼠巨噬細(xì)胞免疫功能的影響[J]. ?細(xì)胞與分子免疫學(xué)雜志, 2012,28(4):374-376,380.
[10]WANG Z, ZHANG X, WANG H, et al. Neuroprotective effects of icaritin against beta amyloid-induced neurotoxicity in primary cultured rat neuronal cells viaestrogen-dependent pathway[J]. ?Neuroscience, 2007,145(3):911-922.
[11]JIANG Mingchun, CHEN Xiaohan, ZHAO Xia, et al. Involvement of IGF-1 receptor signaling pathway in the neuroprotective effects of Icaritin against MPP+-induced toxicity in MES23.5 cells[J]. ?European Journal of Pharmacology, 2016,786:53-59.
[12]MONTESINOS J, ALFONSO-LOECHES S, GUERRI C. Impact of the innate immune response in the actions of ethanol on the central nervous system[J]. ?Alcoholism, Clinical and Experimental Research, 2016,40(11):2260-2270.
[13]LEONOUDAKIS D, RANE A, ANGELI S, et al. Anti-inflammatory and neuroprotective role of natural product securinine in activated glial cells:implications for Parkinsons disease[J]. ?Mediators of Inflammation, 2017, 2017(1):1-11.
[14]SERRANO-POZO A, MUZIKANSKY A, GOMEZ-ISLA T A, et al. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease[J]. ?Journal of Neuropathology and Experimental Neurology, 2013,72(6):462-471.
[15]LU Xiaofeng, MA Lili, RUAN Lingfei, et al. Resveratrol differentially modulates inflammatory responses of microglia and astrocytes[J]. ?Journal of Neuroinflammation, 2010,7(1):46.
[16]HUANG Wenjun, ZENG Shaohua, XIAO Gong, et al. Elucidating the biosynthetic and regulatory mechanisms of flavonoid-derived bioactive components in Epimedium sagittatum[J]. ?Frontiers in Plant Science, 2015,6(1):689-713.
[17]WU Jinfeng, ZHOU Junmin, CHEN Xianghong, et al. Atte-nuation of LPS-induced inflammation by ICT, a derivate of ica-riin, via inhibition of the CD14/TLR4 signaling pathway in human monocytes[J]. ?International Immunopharmacology, 2012,12(1):74-79.
[18]ZHANG Lang, FAN Ya, SU Hanwen, et al. Chlorogenic acid methyl ester exerts strong anti-inflammatory effects via inhibiting the COX-2/NLRP3/NF-κB pathway[J]. ?Food & Function, 2018,9(12):6156-6165.
[19]ZHAO D, KWON S H, CHUN Y S, et al. Anti-neuroinflammatory effects of fucoxanthin via inhibition of Akt/NF-kappa B and MAPKs/AP-1 pathways and activation of PKA/CREB pathway in lipopolysaccharide-activated BV-2 microglial cells[J]. ?Neurochemical Research, 2017,42(2):667-677.
[20]任曉璠,孫憲昌,王宇鑫,等. Rg1和GR阻斷劑對(duì)脂多糖誘導(dǎo)的BV2小膠質(zhì)細(xì)胞iNOS及COX2蛋白表達(dá)影響[J]. ?青島大學(xué)醫(yī)學(xué)院學(xué)報(bào), 2016,52(2):148-149,152.
[21]WASIF N, MCCULLOUGH A E, GRAY R J, et al. Inf-luence of uncommon histology on breast conservation therapy for breast cancer-biology dictates technique[J]? Journal of Surgical Oncology, 2012,105(6):586-590.
[22]BONKHOFF H. Estrogen receptor signaling in prostate can-cer: implications for carcinogenesis and tumor progression[J]. ?The Prostate, 2018,78(1):2-10.
[23]XIAO Huihui, GAO Quangui, ZHANG Yan, et al. Vanillic acid exerts oestrogen-like activities in osteoblast-like UMR 106 cells through MAP kinase(MEK/ERK)-mediated ER signaling pathway[J]. ?Journal of Steroid Biochemistry and Molecular Biology, 2014,144(B):382-391.
[24]葉海涌,劉健,樓宜嘉. 淫羊藿苷衍生物的制備及其雌激素樣作用研究[J]. ?浙江大學(xué)學(xué)報(bào)(醫(yī)學(xué)版), 2005,34(2):40-45.
青島大學(xué)學(xué)報(bào)(醫(yī)學(xué)版)2019年1期